Dianthus Therapeutics, Inc. /DE/ Stock Split Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Stock Split Ratio of 6.25% as of 2023-09-11, per its 8-K filed 2023-12-21.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-12-21
- Dianthus Therapeutics, Inc. /DE/ stockholders' equity note, stock split, conversion ratio for fiscal 2017 was 38.70%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|
| 2023-09-11 | 6.25% 8-K · filed 2023-12-21 | ||
| 2018-06-30 | 38.70% 10-K · filed 2019-03-19 | ||
| 2018-06-06 | 38.70% 10-K · filed 2019-03-19 | ||
| 2017-12-31 | 38.70% 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |